Cue Biopharma, Inc. (CUE)

Market Cap	23.38M -62.1%
Revenue (ttm)	27.47M +195.7%
Net Income	-26.60M
EPS	-0.28
Shares Out	97.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,140,377
Open	0.2409
Previous Close	0.2509
Day's Range	0.2224 - 0.2417
52-Week Range	0.2224 - 1.0500
Beta	1.55
Analysts	Strong Buy
Price Target	3.00 (+1,153.13%)
Earnings Date	Mar 16, 2026

About CUE

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a bifunctional fusion protein designed to promote immune tolerance by inducing iTregs from Teff cells which is in preclinical trial; and CUE-501, a treatment of autoimmune disease via anti-viral T cell-mediated depletion of B cells. The company also develops CUE-101, which is in phase 1b clinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 2, 2018
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: CUE
• Website: https://www.cuebiopharma.com

Financial Performance

In 2025, Cue Biopharma's revenue was $27.47 million, an increase of 195.75% compared to the previous year's $9.29 million. Losses were -$26.60 million, -34.60% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for CUE stock is "Strong Buy." The 12-month stock price target is $3.0, which is an increase of 1,153.13% from the latest price.

Price Target

$3.0

(1,153.13% upside)

Analyst Consensus: Strong Buy